Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer

Helen M. Coley, Eleftheria Hatzimichael, Sarah Blagden, Iain McNeish, Alastair Thompson, Tim Crook, Nelofer Syed

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    The polo-like kinase PLK2 has recently been identified as a potential theranostic marker in the management of chemotherapy sensitive cancers. The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines. Importantly, extrapolation of these in vitro data to the clinical setting confirms that the methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin & paclitaxel chemotherapy. A second cell cycle regulator, p57Kip2, is also subject to epigenetic silencing in carboplatin resistance in vitro and in vivo, emphasising that cell cycle regulators are important determinants of sensitivity to chemotherapeutic agents and providing insights into the phenomenon of collateral drug sensitivity in oncology. Understanding the mechanistic basis and identification of robust biomarkers to predict collateral sensitivity may inform optimal use of chemotherapy in patients receiving multiple lines of treatment.

    Original languageEnglish
    Pages (from-to)78-83
    Number of pages6
    JournalOncotarget
    Volume3
    Issue number1
    Publication statusPublished - Jan 2012

    Cite this